GlassScriptPhysician profile
Rehan Muttalib
NPI 1679068506
$6,316.89
in general payments reported to CMS, 2019-2025
34 companies · $1,182 in 2025
The $1,182 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $584 · 2022: $1,968 · 2023: $1,481 · 2024: $1,102 · 2025: $1,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,758 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,758.32 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,119.95 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $882.07 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $518.20 | 2021-2025 | |
| Lilly USA, LLC | $492.57 | 2021-2025 | Jardiance, Emgality, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $466.53 | 2021-2025 | Xifaxan |
| Almatica Pharma LLC | $436.37 | 2022-2025 | Loreev Xr, Gralise |
| Astellas Pharma US INC | $328.04 | 2021-2024 | Veozah |
| Pfizer INC. | $298.85 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $243.91 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $235.32 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $143.18 | 2023-2024 | Verquvo, Steglatro, Belsomra |
| Novartis Pharmaceuticals Corporation | $109.33 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.58 | 2025 | Lifevest |
| Abbott Laboratories | $94.61 | 2022-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $77.10 | 2022-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $68.69 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.88 | 2025 | Caplyta |
| Amgen INC. | $60.94 | 2023 | Evenity, Prolia, Otezla |
| Dexcom, INC. | $54.52 | 2022-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.59 | 2023-2024 | Jardiance |
| Glaxosmithkline, LLC. | $49.29 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Xeris Pharmaceuticals, INC. | $45.38 | 2022-2025 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $43.38 | 2022 | |
| Eisai INC. | $43.22 | 2022-2024 | |
| Biogen, INC. | $38.22 | 2021-2025 | Leqembi |
| Kowa Pharmaceuticals America, INC. | $35.77 | 2022-2024 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $33.30 | 2025 | Austedo Xr |
| Lundbeck LLC | $31.70 | 2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $30.58 | 2022 | |
| Corcept Therapeutics | $27.91 | 2024 | Korlym |
| Phathom Pharmaceuticals, INC. | $27.01 | 2024 | Voquezna |
| Medtronic, INC. | $21.56 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.22 | 2024 | |
| Smith+Nephew, INC. | $15.12 | 2025 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rehan Muttalib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.